A clinical trial by the Cris Against Cancer Foundation has shown that the drug ponatinib can offer a second chance to patients with chronic myeloid leukemia who had relapsed after stopping their treatment. After two years on the medication, 68.2% of participants managed to keep the disease under control for one year without needing pills. For the public, this means many patients could live without daily medication, improving their quality of life and reducing medical costs.
Mechanism of action and clinical trial design 🧬
Ponatinib is a third-generation tyrosine kinase inhibitor, designed to block the BCR-ABL protein, even in mutations resistant to other drugs. In this study, patients received the medication for two years before stopping it. The key to the protocol was constant molecular monitoring: if the leukemic burden increased, therapy was resumed. The result shows that an intermittent treatment strategy, based on a potent inhibitor, can induce sustained remission without the need for continuous maintenance. This suggests a change in the management of the disease.
Goodbye pills, hello quality of life (and pharmacy savings) 💊
That 68% of patients can leave the pill bottle in the cupboard for a whole year is almost a miracle. Especially when you consider the savings it entails: fewer doctor visits, fewer side effects, and, incidentally, fewer arguments with the pharmacy over the price of the treatment. Of course, there is always the other 31.8% who will still have to stock up on tablets. But hey, for such a stubborn disease, getting a twelve-month break from medication sounds like a paid vacation.